Company / Shareholders' Equity
CAPRICOR THERAPEUTICS, INC. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$305.8M
FY2025
5-year range
$11.8M / $305.8M
FY2021-FY2025
Trend
+110.2%
vs FY2024
Sector context
#128 of 213
Health Care
What the data says
At $306M, CAPRICOR THERAPEUTICS, INC.'s shareholders' equity ranks #128 of 213 in the Health Care sector. Shareholders' Equity has increased for 3 consecutive years, from $12M in FY2022 to $306M in FY2025.
Based on SEC 10-K filings.
$306M in FY2025 with a 5-year CAGR of +61.1%.
Improved from $23M to $306M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +196.0%
- 5-Year CAGR
- +61.1%
- 10-Year CAGR
- -
Sector benchmark
#128 of 213 in Health CareTop 60% of 213This company $305.8M Sector average $2.5B
▼
-88.0% below sector average
Key checks
Key Insights
- CAPRICOR THERAPEUTICS, INC.'s shareholders' equity has grown for 3 consecutive years.
- 5-year CAGR of +61.1%, indicating consistent growth.
- In FY2025, shareholders' equity increased 110.2% year-over-year.
- Ranks #128 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $305.8M | +110.2% |
| FY2024 | $145.5M | +543.6% |
| FY2023 | $22.6M | +91.8% |
| FY2022 | $11.8M | -62.4% |
| FY2021 | $31.4M | +11.2% |
| FY2020 | $28.2M | +511.0% |
| FY2019 | $4.6M | +0.0% |
| FY2018 | $4.6M | -58.9% |
| FY2017 | $11.2M | +380.5% |
| FY2016 | -$4.0M | -288.0% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026